HealthTech Innovation Days

SeaBeLife Biotech

Description

SeaBeLife is pioneering a first-in-class approach to preventing organ failure by targeting dual inhibition of necroptosis and ferroptosis, pathways involved in severe liver and retinal diseases. Currently, we are advancing two assets through preclinical development: SBL01, designed to address life-threatening orphan and acute liver diseases, and SBL03, aiming to preserve vision in Dry-AMD patients, a leading cause of blindness globally among the elderly. These initiatives promise to transform patient outcomes, addressing significant social, economic, and healthcare challenges.

Company members

Morgane Rousselot